8-K current report · filed Nov 16, 2026

MapLight Therapeutics, Inc. (MPLT) 8-K Current Report: November 16, 2026

Item 1.01MPLT overview

Short answer

MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). ATM facility authorizes up to $100 million in common-stock sales, providing MapLight flexible funding access.

MapLight Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • ATM facility authorizes up to $100 million in common-stock sales, providing MapLight flexible funding access
  • Potential equity issuance creates shareholder dilution risk, depending on shares sold
  • Leerink Partners commission up to 3.0% of gross sales, reducing net proceeds
  • Company controls timing, with no obligation to sell and ability to suspend or terminate the agreement

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MapLight Therapeutics, Inc. 8-K filings

Get the next MPLT 8-K as it lands

Follow MPLT for push alerts, or ask the research agent what this filing means.